|10-05-2018 03:04 PM CET - Health & Medicine||
Comprehensive Study on Idiopathic Pulmonary Fibrosis Market 2018 Global Analysis By Top Key Companies– MediciNova, Inc.Boehringer Ingelheim, Roche Pharma DK, FibroGen, Inc., Promedior, Inc., Merck, Galapagos, Prometic Plasma Resources, Cipla
Press release from: Research for Markets
MediciNova, Inc.Boehringer Ingelheim, Roche Pharma DK, FibroGen, Inc., Promedior, Inc., Merck, Galapagos are the leading companies and brands that are driving the Idiopathic Pulmonary Fibrosis Market. The CAGR numbers are looking quite impressive for the forecast period of 2018-2023 in the Idiopathic Pulmonary Fibrosis Market. The sales, import, export and revenue figures are also skyrocketing in the forecast period. The key players and brands are making their moves by product launches, their researches, their joint ventures, merges, and accusations and are getting successful results.
Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.
This report studies the Idiopathic Pulmonary Fibrosis market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Idiopathic Pulmonary Fibrosis market by product type and applications/end industries.
Get Free Sample Copy of Report www.researchformarkets.com/sample/global-idiopathic-pulmo...
The following manufacturers are covered in this report:
• MediciNova, Inc.
• Boehringer Ingelheim
• Roche Pharma DK
• FibroGen, Inc.
• Promedior, Inc.
• Prometic Plasma Resources
Market Segment by Regions, regional analysis covers
• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia and Italy)
• Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
• South America (Brazil, Argentina, Colombia)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
• Systemic Corticosteroids
• Immunosuppressant Drugs
• Tyrosine Kinase Inhibitors
• Antifibrotic Agents
Market Segment by Applications, can be divided into
• Ambulatory Surgical Centers
• Academic and Research Organizations
Get More Information about this report www.researchformarkets.com/reports/global-idiopathic-pulm...
Table of Content:
1 Market Overview
2 Manufacturers Profiles
3 Global Idiopathic Pulmonary Fibrosis Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
4 Global Idiopathic Pulmonary Fibrosis Market Analysis by Regions
5 North America Idiopathic Pulmonary Fibrosis by Countries
6 Europe Idiopathic Pulmonary Fibrosis by Countries
7 Asia-Pacific Idiopathic Pulmonary Fibrosis by Countries
8 South America Idiopathic Pulmonary Fibrosis by Countries
9 Middle East and Africa Idiopathic Pulmonary Fibrosis by Countries
10 Global Idiopathic Pulmonary Fibrosis Market Segment by Type
11 Global Idiopathic Pulmonary Fibrosis Market Segment by Application
12 Idiopathic Pulmonary Fibrosis Market Forecast (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
14 Research Findings and Conclusion
Note: If you have any special requirements, please let us know and we will offer you the report as you want.
Scope of the Report:
•This report studies the Idiopathic Pulmonary Fibrosis market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Idiopathic Pulmonary Fibrosis market by product type and applications/end industries.
•An increase in the incidence and prevalence of fibrotic diseases is the primary driver for the growth of this market. Idiopathic pulmonary fibrosis most commonly affects middle-aged to older adults and is characterized by the scarring of lung tissues. In older people, these scars tend to build up and affect the normal functioning of lungs. Thus, an increase in aging population leads to increased prevalence of the disease, which in turn results in market growth during the predicted period.
•The global Idiopathic Pulmonary Fibrosis market is valued at 1620 million USD in 2017 and is expected to reach 3120 million USD by the end of 2023, growing at a CAGR of 11.5% between 2017 and 2023.
•The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
•North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Idiopathic Pulmonary Fibrosis.
•Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Purchase This Report at www.researchformarkets.com/buy-now/global-idiopathic-pulm...
Research For Markets indulge in detailed and diligent research on different markets, trends and emerging opportunities in the successive direction to cater to your business needs. We have established the pillars of our flourishing institute on the grounds of Credibility and Reliability. RFM delve into the markets across Asia Pacific, North America, South America, Europe, Middle East And Africa.
Level 21, Dashwood House
69 Old Broad Street
London EC2M 1QS, United Kingdom
This release was published on openPR.
News-ID: 1284098 • Views: 233More releases